Kristopher M. Kirmess
YOU?
Author Swipe
View article: Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium
Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium Open
INTRODUCTION Blood‐based biomarkers (BBMs) have revolutionized Alzheimer's disease diagnosis and monitoring. Their pre‐analytical stability requires scrutiny. This study assessed pre‐analytical effects to inform a standardized sample handl…
View article: Prolonged fasting promotes systemic inflammation and platelet activation in humans: A medically supervised, water-only fasting and refeeding study
Prolonged fasting promotes systemic inflammation and platelet activation in humans: A medically supervised, water-only fasting and refeeding study Open
View article: Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls
Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls Open
INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta‐amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ 42/40 , phosphorylated‐tau (p‐tau), n…
View article: Predicting PET‐Based Amyloid and Tau Pathology Stages With Plasma Biomarkers in Alzheimer's disease
Predicting PET‐Based Amyloid and Tau Pathology Stages With Plasma Biomarkers in Alzheimer's disease Open
Background We aimed to investigate whether the quantitative analysis of plasma biomarkers could distinguish the pathology stages indicated by positron emission tomography (PET)‐based Thal phase of amyloid and Braak stage of tau. Method A t…
View article: Diagnostic Performance of Plasma Biomarkers for A/T/N Image Classification in Alzheimer's disease
Diagnostic Performance of Plasma Biomarkers for A/T/N Image Classification in Alzheimer's disease Open
Background We aimed to validate the ability of Alzheimer’s disease plasma biomarkers to predict clinical diagnosis and the ability to predict image‐based A/T/N biomarkers positivity in Asian population. We also sought to define the optimal…
View article: PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology Open
Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging modalities…
View article: PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations that are Used with Plasma Amyloid-β42/40 in a Multiple Analyte Assay with Algorithm for Detecting Brai
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations that are Used with Plasma Amyloid-β42/40 in a Multiple Analyte Assay with Algorithm for Detecting Brai Open
Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging moda…
View article: Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid Open
BACKGROUND With the availability of disease‐modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receivi…
View article: Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset
Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset Open
Objective A clock relating amyloid positron emission tomography (PET) to time was used to estimate the timing of biomarker changes in sporadic Alzheimer disease (AD). Methods Research participants were included who underwent cerebrospinal …
View article: Apathy, cognition and beta amyloid in African Americans in the AA‐FAIM cohort
Apathy, cognition and beta amyloid in African Americans in the AA‐FAIM cohort Open
Background The prodrome of cognitive declines and/or dementia may include late‐life neuropsychiatric symptoms such as apathy. In primarily non‐Hispanic White samples, apathy associates with both cognition and amyloid deposition in cognitiv…
View article: Blood Biomarkers Improve The Diagnostic Accuracy Of Alzheimer’s Disease As Compared With Current Diagnostic Standard In the Primary Care Setting
Blood Biomarkers Improve The Diagnostic Accuracy Of Alzheimer’s Disease As Compared With Current Diagnostic Standard In the Primary Care Setting Open
Background The first and final level of care for most individuals with cognitive impairment is primary care. The aim was to examine the diagnostic accuracy of plasma phospho‐tau217/non‐phospho‐Tau217 (p‐tau217 Ratio) and Aβ42/40 Ratio for …
View article: Social support, plasma amyloid, and cognitive function: Findings on cognitive resilience from the African Americans Fighting Alzheimer’s in Midlife (AA‐FAIM) study
Social support, plasma amyloid, and cognitive function: Findings on cognitive resilience from the African Americans Fighting Alzheimer’s in Midlife (AA‐FAIM) study Open
Background Epidemiological evidence suggests that excess risk for Alzheimer’s disease and related dementias (ADRD) in minoritized populations is preventable. Social connectedness associates with reduced ADRD risk: plausible mechanisms incl…
View article: Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease
Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease Open
INTRODUCTION Incorporating blood‐based Alzheimer's disease biomarkers such as tau and amyloid beta (Aβ) into screening algorithms may improve screening efficiency. METHODS Plasma Aβ, phosphorylated tau (p‐tau)181, and p‐tau217 concentratio…
View article: Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA‐FAIM cohort
Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA‐FAIM cohort Open
Introduction It is critical to develop more inclusive Alzheimer's disease (AD) research protocols to ensure that historically excluded groups are included in preclinical research and have access to timely diagnosis and treatment. If valida…
View article: Independent study demonstrates amyloid probability score accurately indicates amyloid pathology
Independent study demonstrates amyloid probability score accurately indicates amyloid pathology Open
Background The amyloid probability score (APS) is the model read‐out of the analytically validated mass spectrometry‐based PrecivityAD ® blood test that incorporates the plasma Aβ42/40 ratio, ApoE proteotype, and age to identify the likeli…
View article: Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 Open
Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid be…
View article: Comparison of plasma and <scp>CSF</scp> biomarkers in predicting cognitive decline
Comparison of plasma and <span>CSF</span> biomarkers in predicting cognitive decline Open
Objectives Concentrations of amyloid‐β peptides (Aβ42/Aβ40) and neurofilament light (NfL) can be measured in plasma or cerebrospinal fluid (CSF) and are associated with Alzheimer’s disease brain pathology and cognitive impairment. This stu…
View article: Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light Open
Models predicting brain amyloidosis using a high-performance plasma Aβ42/Aβ40 assay may provide an accurate and consistent measure of brain amyloidosis across AA and NHW groups, but models based on plasma p-tau181, p-tau231, and NfL may pe…
View article: Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment Open
These findings suggest that this blood biomarker test could allow for distinguishing individuals with brain amyloid-positive PET findings from individuals with amyloid-negative PET findings and serve as an aid for Alzheimer disease diagnos…
View article: Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group Open
Introduction Pre‐analytical sample handling might affect the results of Alzheimer's disease blood‐based biomarkers. We empirically tested variations of common blood collection and handling procedures. Methods We created sample sets that ad…
View article: The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis Open
View article: A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis Open
View article: INSIGHTS INTO PROTON TRANSFER MECHANISMS IN HALOGEN-SUBSTITUTED MALDI MATRICES
INSIGHTS INTO PROTON TRANSFER MECHANISMS IN HALOGEN-SUBSTITUTED MALDI MATRICES Open
As polycyclic aromatic hydrocarbons (PAHs) are of interest to many communities, including astronomers, it is important to understand the interactions that they may be a part of. As water is ubiquitous in astronomical environments and PAHs …
View article: Tau Kinetics in Neurons and the Human Central Nervous System
Tau Kinetics in Neurons and the Human Central Nervous System Open
View article: INSIGHT INTO THE CHARGE TRANSFER MECHANISMS OF HEAVY ATOM SUBSTITUTED MALDI MATRICES
INSIGHT INTO THE CHARGE TRANSFER MECHANISMS OF HEAVY ATOM SUBSTITUTED MALDI MATRICES Open
The underlying mechanism of how MALDI matrices work is poorly understood. Experimental literature suggests that the triplet excited state (T$_{1}$) of the matrix plays a significant role in its ability to transfer charge to the analyte eff…
View article: Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide
Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide Open
Neuroendocrine prostate cancer is a lethal variant of prostate cancer that is associated with castrate-resistant growth, metastasis, and mortality. The tumor environment of neuroendocrine prostate cancer is heterogeneous and characterized …